Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

July 27, 2018 updated by: Furiex Pharmaceuticals, Inc

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.

Study Overview

Status

Completed

Conditions

Irritable Bowel Syndrome

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

1146

Phase

Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Canada
- British Columbia
  - Kelowna, British Columbia, Canada, V1Y 3G8
    - Furiex research site
- Newfoundland and Labrador
  - St. John's, Newfoundland and Labrador, Canada, A1E 2E2
    - Furiex research site
- Ontario
  - Burlington, Ontario, Canada, L7M 4Y1
    - Furiex research site
  - Hawkesbury, Ontario, Canada, K6A 1A1
    - Furiex research site
  - London, Ontario, Canada, N5W 6A2
    - Furiex research site
  - Newmarket, Ontario, Canada, L3Y 5G8
    - Furiex research site
  - Sarnia, Ontario, Canada, N7T 4X3
    - Furiex research site
  - Sudbury, Ontario, Canada, P3E 1H5
    - Furiex research site
  - Toronto, Ontario, Canada, M6H 3M1
    - Furiex research site
  - Vaughan, Ontario, Canada, L4L 4Y7
    - Furiex research site
Puerto Rico
- - San Juan, Puerto Rico, 00926-2832
    - Furiex research site
United Kingdom
- - Birmingham, United Kingdom, B15 2TH
    - Furiex research site
  - County Durham, United Kingdom, DL14 6AD
    - Furiex research site
  - Coventry, United Kingdom, CV2 2DX
    - Furiex research site
  - Durham, United Kingdom, DH1 5TW
    - Furiex research site
  - Edinburgh, United Kingdom, EH4 2XH
    - Furiex research site
  - Manchester, United Kingdom, M23 9LT
    - Furiex research site
  - Sheffield, United Kingdom, S10 2JF
    - Furiex research site
  - Wigan, United Kingdom, WN1 2NN
    - Furiex research site
- Kent
  - Chestfield, Kent, United Kingdom, CT5 3QS
    - Furiex research site
- Lancashire
  - Blackpool, Lancashire, United Kingdom, FY4 3AD
    - Furiex research site
United States
- Alabama
  - Birmingham, Alabama, United States, 35209
    - Furiex research site
  - Birmingham, Alabama, United States, 35242
    - Furiex research site
  - Decatur, Alabama, United States, 35603
    - Furiex research site
  - Huntsville, Alabama, United States, 35801
    - Furiex research site
  - Mobile, Alabama, United States, 36608
    - Furiex research site
  - Montgomery, Alabama, United States, 36109
    - Furiex research site
  - Sheffield, Alabama, United States, 35660
    - Furiex research site
  - Tuscaloosa, Alabama, United States, 35401
    - Furiex research site
- Arizona
  - Glendale, Arizona, United States, 85306
    - Furiex research site
  - Glendale, Arizona, United States, 85308
    - Furiex research site
  - Mesa, Arizona, United States, 85206
    - Furiex research site
  - Phoenix, Arizona, United States, 85023
    - Furiex research site
  - Phoenix, Arizona, United States, 85032
    - Furiex research site
  - Tucson, Arizona, United States, 85712
    - Furiex research site
  - Tucson, Arizona, United States, 85704
    - Furiex research site
- Arkansas
  - Jonesboro, Arkansas, United States, 72401
    - Furiex research site
  - Little Rock, Arkansas, United States, 72205
    - Furiex research site
  - Sherwood, Arkansas, United States, 72120
    - Furiex research site
- California
  - Anaheim, California, United States, 92801
    - Furiex research site
  - Chula Vista, California, United States, 91910
    - Furiex research site
  - Encinitas, California, United States, 92024
    - Furiex research site
  - Garden Grove, California, United States, 92840
    - Furiex research site
  - Huntington Beach, California, United States, 92647
    - Furiex research site
  - Irvine, California, United States, 92604
    - Furiex research site
  - La Mesa, California, United States, 91942
    - Furiex research site
  - La Mirada, California, United States, 90638
    - Furiex research site
  - Laguna Hills, California, United States, 92653
    - Furiex research site
  - Lakewood, California, United States, 90805
    - Furiex research site
  - Lincoln, California, United States, 95648
    - Furiex research site
  - Loma Linda, California, United States, 92354
    - Furiex research site
  - Lomita, California, United States, 90717
    - Furiex research site
  - Long Beach, California, United States, 90806
    - Furiex research site
  - Los Angeles, California, United States, 90045
    - Furiex research site
  - Newport Beach, California, United States, 92663
    - Furiex research site
  - North Hollywood, California, United States, 91606
    - Furiex research site
  - Northridge, California, United States, 91325
    - Furiex research site
  - Pasadena, California, United States, 91105
    - Furiex research site
  - Sacramento, California, United States, 95817
    - Furiex research site
  - San Diego, California, United States, 92103
    - Furiex research site
  - San Diego, California, United States, 92105
    - Furiex research site
  - Santa Ana, California, United States, 92701
    - Furiex research site
  - Ventura, California, United States, 93003
    - Furiex research site
  - Walnut Creek, California, United States, 94598
    - Furiex research site
- Colorado
  - Denver, Colorado, United States, 80211
    - Furiex research site
  - Denver, Colorado, United States, 80246
    - Furiex research site
- Florida
  - Boca Raton, Florida, United States, 33428
    - Furiex research site
  - Boynton Beach, Florida, United States, 33426
    - Furiex research site
  - Bradenton, Florida, United States, 34208
    - Furiex research site
  - Brooksville, Florida, United States, 34601
    - Furiex research site
  - Clearwater, Florida, United States, 33759
    - Furiex research site
  - Cooper City, Florida, United States, 33024
    - Furiex research site
  - Coral Springs, Florida, United States, 33065
    - Furiex research site
  - Eustis, Florida, United States, 32726
    - Furiex research site
  - Fort Lauderdale, Florida, United States, 33308
    - Furiex research site
  - Hallandale Beach, Florida, United States, 33009
    - Furiex research site
  - Hialeah, Florida, United States, 33016
    - Furiex research site
  - Jacksonville, Florida, United States, 32205
    - Furiex research site
  - Jupiter, Florida, United States, 33458
    - Furiex research site
  - Lauderdale Lakes, Florida, United States, 33319
    - Furiex research site
  - Melbourne, Florida, United States, 32901
    - Furiex research site
  - Miami, Florida, United States, 33015
    - Furiex research site
  - Miami, Florida, United States, 33125
    - Furiex research site
  - Miami, Florida, United States, 33126
    - Furiex research site
  - Miami, Florida, United States, 33133
    - Furiex research site
  - Miami, Florida, United States, 33135
    - Furiex research site
  - Miami, Florida, United States, 33144
    - Furiex research site
  - Miami, Florida, United States, 33155
    - Furiex research site
  - Miami, Florida, United States, 33183
    - Furiex research site
  - Miramar, Florida, United States, 33025
    - Furiex research site
  - New Port Richey, Florida, United States, 34652
    - Furiex research site
  - Orlando, Florida, United States, 32806
    - Furiex research site
  - Plant City, Florida, United States, 33563
    - Furiex research site
  - Port Orange, Florida, United States, 32127
    - Furiex research site
  - Saint Petersburg, Florida, United States, 33709
    - Furiex research site
  - Saint Petersburg, Florida, United States, 33705
    - Furiex research site
  - South Miami, Florida, United States, 33143
    - Furiex research site
  - Tampa, Florida, United States, 33607
    - Furiex research site
  - Wellington, Florida, United States, 33414
    - Furiex research site
  - Winter Haven, Florida, United States, 33880
    - Furiex research site
  - Winter Park, Florida, United States, 32792
    - Furiex research site
- Georgia
  - Alpharetta, Georgia, United States, 30005
    - Furiex research site
  - Athens, Georgia, United States, 30606
    - Furiex research site
  - Atlanta, Georgia, United States, 30338
    - Furiex research site
  - Atlanta, Georgia, United States, 30308
    - Furiex research site
  - Dunwoody, Georgia, United States, 30338
    - Furiex research site
  - Lawrenceville, Georgia, United States, 30046
    - Furiex research site
  - Macon, Georgia, United States, 31201
    - Furiex research site
  - Marietta, Georgia, United States, 30066
    - Furiex research site
  - Norcross, Georgia, United States, 30092
    - Furiex research site
  - Savannah, Georgia, United States, 31404
    - Furiex research site
  - Stockbridge, Georgia, United States, 30281
    - Furiex research site
- Idaho
  - Boise, Idaho, United States, 83704
    - Furiex research site
  - Eagle, Idaho, United States, 83616
    - Furiex research site
  - Idaho Falls, Idaho, United States, 83404
    - Furiex research site
- Illinois
  - Addison, Illinois, United States, 60101
    - Furiex research site
  - Chicago, Illinois, United States, 60612
    - Furiex research site
  - Chicago, Illinois, United States, 60622
    - Furiex research site
  - Evergreen Park, Illinois, United States, 60805
    - Furiex research site
  - Hammond, Illinois, United States, 46324
    - Furiex research site
  - Springfield, Illinois, United States, 62703
    - Furiex research site
- Indiana
  - Brownsburg, Indiana, United States, 46112
    - Furiex research site
  - Evansville, Indiana, United States, 47714
    - Furiex research site
  - Granger, Indiana, United States, 46530
    - Furiex research site
- Iowa
  - Clive, Iowa, United States, 50325
    - Furiex research site
- Kansas
  - Pratt, Kansas, United States, 67124
    - Furiex research site
  - Shawnee Mission, Kansas, United States, 66218
    - Furiex research site
  - Topeka, Kansas, United States, 66606
    - Furiex research site
- Kentucky
  - Lexington, Kentucky, United States, 40504
    - Furiex research site
  - Lexington, Kentucky, United States, 40503
    - Furiex research site
  - Owensboro, Kentucky, United States, 42303
    - Furiex research site
  - Paducah, Kentucky, United States, 42003
    - Furiex research site
- Louisiana
  - Lake Charles, Louisiana, United States, 70601
    - Furiex research site
  - Monroe, Louisiana, United States, 71201
    - Furiex research site
- Maryland
  - Hagerstown, Maryland, United States, 21742
    - Furiex research site
  - Hollywood, Maryland, United States, 20636
    - Furiex research site
- Massachusetts
  - Boston, Massachusetts, United States, 02115
    - Furiex research site
  - Boston, Massachusetts, United States, 02131
    - Furiex research site
  - Brockton, Massachusetts, United States, 02302
    - Furiex research site
  - Watertown, Massachusetts, United States, 02472
    - Furiex research site
- Michigan
  - Ann Arbor, Michigan, United States, 48106
    - Furiex research site
  - Bay City, Michigan, United States, 48706
    - Furiex research site
  - Cadillac, Michigan, United States, 49601
    - Furiex research site
  - Grand Rapids, Michigan, United States, 49506
    - Furiex research site
  - Kalamazoo, Michigan, United States, 49009
    - Furiex research site
  - Troy, Michigan, United States, 48098
    - Furiex research site
  - Ypsilanti, Michigan, United States, 48197
    - Furiex research site
- Minnesota
  - Plymouth, Minnesota, United States, 55446
    - Furiex research site
- Mississippi
  - Biloxi, Mississippi, United States, 39531
    - Furiex research site
- Missouri
  - Hazelwood, Missouri, United States, 63042
    - Furiex research site
  - Saint Louis, Missouri, United States, 63128
    - Furiex research site
  - Saint Louis, Missouri, United States, 63141
    - Furiex research site
  - Saint Louis, Missouri, United States, 63122
    - Furiex research site
  - Saint Peters, Missouri, United States, 63376
    - Furiex research site
- Montana
  - Billings, Montana, United States, 59101
    - Furiex research site
- Nebraska
  - Bellevue, Nebraska, United States, 68005
    - Furiex research site
  - Elkhorn, Nebraska, United States, 68022
    - Furiex research site
  - Lincoln, Nebraska, United States, 68510
    - Furiex research site
  - Omaha, Nebraska, United States, 68134
    - Furiex research site
  - Omaha, Nebraska, United States, 68144
    - Furiex research site
- Nevada
  - Las Vegas, Nevada, United States, 89123
    - Furiex research site
  - Reno, Nevada, United States, 89511
    - Furiex research site
- New Hampshire
  - Lebanon, New Hampshire, United States, 03756
    - Furiex research site
- New Jersey
  - Blackwood, New Jersey, United States, 08012
    - Furiex research site
  - Edison, New Jersey, United States, 08817
    - Furiex research site
  - Elizabeth, New Jersey, United States, 07201
    - Furiex research site
  - Marlton, New Jersey, United States, 08053
    - Furiex research site
- New Mexico
  - Albuquerque, New Mexico, United States, 87102
    - Furiex research site
  - Albuquerque, New Mexico, United States, 87108
    - Furiex research site
  - Albuquerque, New Mexico, United States, 87109
    - Furiex research site
- New York
  - Flushing, New York, United States, 11367
    - Furiex research site
  - Hollis, New York, United States, 11423
    - Furiex research site
  - Mineola, New York, United States, 11501
    - Furiex research site
  - New York, New York, United States, 10016
    - Furiex research site
- North Carolina
  - Chapel Hill, North Carolina, United States, 27599
    - Furiex research site
  - Dunn, North Carolina, United States, 28334
    - Furiex research site
  - Greensboro, North Carolina, United States, 27403
    - Furiex research site
  - Huntersville, North Carolina, United States, 28078
    - Furiex research site
  - Kinston, North Carolina, United States, 28501
    - Furiex research site
  - Wilmington, North Carolina, United States, 28403
    - Furiex research site
  - Winston-Salem, North Carolina, United States, 27103
    - Furiex research site
  - Winston-Salem, North Carolina, United States, 27106
    - Furiex research site
- Ohio
  - Akron, Ohio, United States, 44302
    - Furiex research site
  - Beavercreek, Ohio, United States, 45431
    - Furiex research site
  - Cincinnati, Ohio, United States, 45224
    - Furiex research site
  - Cincinnati, Ohio, United States, 45242
    - Furiex research site
  - Cincinnati, Ohio, United States, 45245
    - Furiex research site
  - Cincinnati, Ohio, United States, 45267
    - Furiex research site
  - Cleveland, Ohio, United States, 44122
    - Furiex research site
  - Columbus, Ohio, United States, 43214
    - Furiex research site
  - Columbus, Ohio, United States, 43212
    - Furiex research site
  - Columbus, Ohio, United States, 43235
    - Furiex research site
  - Dayton, Ohio, United States, 45432
    - Furiex research site
  - Dayton, Ohio, United States, 45439
    - Furiex research site
  - Groveport, Ohio, United States, 43125
    - Furiex research site
  - Kettering, Ohio, United States, 45429
    - Furiex research site
  - Lima, Ohio, United States, 45806
    - Furiex research site
  - Tiffin, Ohio, United States, 44883
    - Furiex research site
  - Toledo, Ohio, United States, 43615
    - Furiex research site
- Oklahoma
  - Norman, Oklahoma, United States, 73071
    - Furiex research site
  - Oklahoma City, Oklahoma, United States, 73112
    - Furiex research site
  - Oklahoma City, Oklahoma, United States, 73102
    - Furiex research site
- Oregon
  - Portland, Oregon, United States, 97210
    - Furiex research site
  - Salem, Oregon, United States, 97301
    - Furiex research site
- Pennsylvania
  - Carnegie, Pennsylvania, United States, 15106
    - Furiex research site
  - Philadelphia, Pennsylvania, United States, 19107
    - Furiex research site
  - Pittsburgh, Pennsylvania, United States, 15243
    - Furiex research site
  - Pittsburgh, Pennsylvania, United States, 15206
    - Furiex research site
  - Scottdale, Pennsylvania, United States, 15683
    - Furiex research site
  - Uniontown, Pennsylvania, United States, 15401
    - Furiex research site
- Rhode Island
  - Warwick, Rhode Island, United States, 02888
    - Furiex research site
- South Carolina
  - Anderson, South Carolina, United States, 29621
    - Furiex research site
  - Columbia, South Carolina, United States, 29201
    - Furiex research site
  - Columbia, South Carolina, United States, 29203
    - Furiex research site
  - Columbia, South Carolina, United States, 29204
    - Furiex research site
  - Easley, South Carolina, United States, 29640
    - Furiex research site
  - Mount Pleasant, South Carolina, United States, 29464
    - Furiex research site
  - North Myrtle Beach, South Carolina, United States, 29582
    - Furiex research site
- South Dakota
  - Rapid City, South Dakota, United States, 57702
    - Furiex research site
- Tennessee
  - Athens, Tennessee, United States, 37303
    - Furiex research site
  - Chattanooga, Tennessee, United States, 37404
    - Furiex research site
  - Columbia, Tennessee, United States, 38401
    - Furiex research site
  - Jackson, Tennessee, United States, 38305
    - Furiex research site
  - Knoxville, Tennessee, United States, 37919
    - Furiex research site
  - Smyrna, Tennessee, United States, 37167
    - Furiex research site
- Texas
  - Austin, Texas, United States, 78745
    - Furiex research site
  - Beaumont, Texas, United States, 77701
    - Furiex research site
  - Bedford, Texas, United States, 76021
    - Furiex research site
  - Corsicana, Texas, United States, 75110
    - Furiex research site
  - Dallas, Texas, United States, 75218
    - Furiex research site
  - Dallas, Texas, United States, 75225
    - Furiex research site
  - Fort Worth, Texas, United States, 76133
    - Furiex research site
  - Frisco, Texas, United States, 75035
    - Furiex research site
  - Houston, Texas, United States, 77008
    - Furiex research site
  - Houston, Texas, United States, 77043
    - Furiex research site
  - Houston, Texas, United States, 77062
    - Furiex research site
  - Humble, Texas, United States, 77338
    - Furiex research site
  - Hurst, Texas, United States, 76054
    - Furiex research site
  - San Antonio, Texas, United States, 78229
    - Furiex research site
  - San Antonio, Texas, United States, 78258
    - Furiex research site
  - San Antonio, Texas, United States, 78215
    - Furiex research site
- Utah
  - Bountiful, Utah, United States, 84010
    - Furiex research site
  - Salt Lake City, Utah, United States, 84124
    - Furiex research site
  - West Valley City, Utah, United States, 84120
    - Furiex research site
- Vermont
  - Burlington, Vermont, United States, 05401
    - Furiex research site
- Virginia
  - Alexandria, Virginia, United States, 22304
    - Furiex research site
  - Christiansburg, Virginia, United States, 24073
    - Furiex research site
  - Midlothian, Virginia, United States, 23114
    - Furiex research site
  - Norfolk, Virginia, United States, 23502
    - Furiex research site
  - Richmond, Virginia, United States, 23233
    - Furiex research site
  - Richmond, Virginia, United States, 23235
    - Furiex research site
- West Virginia
  - Charleston, West Virginia, United States, 25304
    - Furiex research site
- Wisconsin
  - Monroe, Wisconsin, United States, 53566
    - Furiex research site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Description

Inclusion Criteria:

Participant is 18 to 80 years old
Participant has a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea defined by the Rome III criteria.

2. Participant has had a colonoscopy performed:

Within 10 years prior to Prescreening if participant is at least 50 years of age (sigmoidoscopy, double contrast barium enema, or computed tomography (CT) colonography within the past 5 years is acceptable)
Since the onset (if applicable) of any of the following alarm features for participants of any age
- Participant has documented weight loss within the past 6 months
- Participant has nocturnal symptoms
- Participant has a familial history of first-degree relatives with colon cancer
- Participant has blood mixed with their stool (excluding blood from hemorrhoids).
  3. Female participants must be:
Postmenopausal, defined as 52 years or older and amenorrheic for at least 2 years at Prescreening,
Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
Abstinent, or
If sexually active, be practicing an effective method of birth control.

Exclusion Criteria:

Participant has a diagnosis of IBS with a subtype of constipation, mixed IBS, or unsubtyped IBS by the Rome III criteria.
Participant has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis) and celiac disease.
Participant has a history of diverticulitis within 3 months prior to Prescreening.
Participant has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, or impaired intestinal circulation (eg, aortoiliac disease).
Participant has any of the following surgical history:
- Cholecystectomy with any history of post cholecystectomy biliary tract pain
- Any abdominal surgery within the 3 months prior to Prescreening
- Participant has a history of major gastric, hepatic, pancreatic, or intestinal surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post surgery are allowed)

Other protocol-specific eligibility criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Triple

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Eluxadoline 75 mg Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.	Drug: Eluxadoline Oral tablets twice daily Other Names: JNJ-27018966
Experimental: Eluxadoline 100 mg Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.	Drug: Eluxadoline Oral tablets twice daily Other Names: JNJ-27018966
Placebo Comparator: Placebo Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.	Drug: Placebo Oral tablets twice daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores Time Frame: Up to 12 weeks	Composite responders were defined as participants who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score <5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.	Up to 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Were Pain Responders In Daily Worst Abdominal Pain Scores by Intervals Time Frame: 12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)	Pain responders were defined as participants who met the daily pain response criteria (ie, the worst abdominal pain score in the past 24 hours improved by ≥30% compared to baseline) for at least 50% of days with diary entries during each interval. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.	12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)
Percentage of Participants With Irritable Bowel Syndrome - Adequate Relief (IBS-AR) Scale Time Frame: 12-week interval (Weeks 1-12) and 26-week interval (Weeks 1-26)	Adequate relief of IBS symptoms was assessed once weekly by participants answering the IBS-AR item in the electronic diary. IBS-AR responders were defined as participants with a weekly response of "Yes" to adequate relief of their IBS symptoms for at least 50% of the total weeks during the interval. A participant must have had a positive response on ≥6 weeks for the 12-week interval and ≥13 weeks for the 26-week interval, regardless of diary compliance, to be a responder.	12-week interval (Weeks 1-12) and 26-week interval (Weeks 1-26)
Change From Baseline in Daily Abdominal Discomfort Scores Time Frame: Baseline, Weeks 4, 12 and 26	Symptoms of abdominal discomfort were recorded on a 0 to 10 scale, where 0 corresponded to no discomfort and 10 corresponded to worst imaginable discomfort. A negative change from Baseline indicates the discomfort decreased.	Baseline, Weeks 4, 12 and 26
Change From Baseline in Daily Abdominal Bloating Scores Time Frame: Baseline, Weeks 4, 12 and 26	Symptoms of abdominal bloating were recorded on a 0 to 10 scale, where 0 corresponded to no bloating and 10 corresponded to worst imaginable bloating. A negative change from Baseline indicates the bloating decreased.	Baseline, Weeks 4, 12 and 26
Number of Bowel Movements Per Day Time Frame: Weeks 4, 12 and 26	Participants recorded the number of bowel movements over 24 hours daily throughout the treatment.	Weeks 4, 12 and 26
Number of Bowel Incontinence Episodes Time Frame: Weeks 4, 12 and 26	Participants recorded the number of incontinence episodes over 24 hours daily throughout the treatment.	Weeks 4, 12 and 26
Number of Bowel Incontinence Free Days Time Frame: Weeks 4, 12 and 26	An incontinence free day was one where the participant reports zero incontinence episodes. The number of incontinence free days for a participant was assessed each week based on the number of reported days.	Weeks 4, 12 and 26
Number of Urgency Episodes Per Day Time Frame: Weeks 4, 12 and 26	Participants recorded the number of urgency episodes over 24 hours daily throughout the treatment.	Weeks 4, 12 and 26
Percentage of Participants Who Were Composite Responders Based on Improvements From Baseline in Daily Worst Abdominal Pain and Daily Stool Consistency Scores Time Frame: Up to 26 weeks	Composite responders were defined as participants who met the daily response criteria for at least 50% of the days with diary entries during the interval of interest. A participant must had met both of the following criteria on a given day to be a daily responder: 1) Daily pain response: worst abdominal pain scores in the past 24 hours improved by ≥30% compared to baseline (average of daily worst abdominal pain the week prior to randomization). 2) Daily stool consistency response: Bristol Stool Scale (BSS) score <5 (ie, score of 1, 2, 3, or 4) or the absence of a bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain. Bristol stool scale was defined as 7-point Scale in which a score of 1 = separate hard lumps, 2 = sausage shaped but lumpy, 3 = sausage-like with cracks on the surface, 4 = sausage-like but smooth and soft, 5 = soft blobs with clear cut edges, 6 = fluffy pieces with ragged edges, and 7 = watery with no solid pieces.	Up to 26 weeks
Percentage of Participants Who Were Responders In Daily Stool Consistency Scores by Intervals Time Frame: 12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)	Stool consistency responders: Participants who met daily stool consistency response criterion (ie,score of 1, 2, 3, or 4 or absence of bowel movement if accompanied by ≥30% improvement in worst abdominal pain compared to baseline pain) for at least 50% of days with diary entries during each interval. BSS was defined as 7-point Scale in which score of 1= separate hard lumps, 2= sausage shaped but lumpy, 3= sausage-like with cracks on the surface, 4= sausage-like but smooth and soft, 5= soft blobs with clear cut edges, 6= fluffy pieces with ragged edges, and 7= watery with no solid pieces. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over 12-week interval, and a minimum of 110 days of diary entries over 26-week interval to be a responder.	12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)
Percentage of Participants Who Were Responders In Irritable Bowel Syndrome, Diarrhea Predominant (IBS-d) Global Symptom Scale by Intervals Time Frame: 12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)	IBS-d global symptom responders were defined as those participants who met the daily IBS-d global symptom response criteria (ie, IBS-d global symptom score of 0 [none] or 1 [mild]; or a daily IBS-d global symptom score improved by ≥2.0 compared to the baseline average) for at least 50% of days with diary entries during each interval. IBS-d Global Symptom Scale was a 5-point scale, score ranging from 0 to 4. 0= no symptoms, 1= mild symptoms, 2= moderate symptoms, 3= severe symptoms and 4 = very severe symptoms. A participant must have had a minimum of 20 days of diary entries over any 4-week interval, a minimum of 60 days of diary entries over the 12-week interval, and a minimum of 110 days of diary entries over the 26-week interval to be a responder.	12-week interval (Weeks 1-12), 26-week interval (Weeks 1-26), and 4-week interval (Weeks 1-4, 5-8, 9-12, 13-16, 17-20, and 21-24)
Percentage of Participants Who Were Responders to the Irritable Bowel Syndrome Quality of Life Measure (IBS-QoL) Scale Time Frame: Weeks 4, 8, 12, 18, 26 and 30 (End of Treatment [EOT])	IBS-QoL responders were defined as participants who achieved at least a 14-point improvement in IBS-QoL total score from baseline to the applicable visit. The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100-point (0= worst; 100=better) scale for ease of interpretation.	Weeks 4, 8, 12, 18, 26 and 30 (End of Treatment [EOT])
Change From Baseline in IBS-QoL Total Scores Time Frame: Baseline, Weeks 4, 8, 12, 18, 26 and 30/EOT	The IBS-QoL consists of 34 items each with a 5-point response scale, where 1 generally represents better responses on items and 5 represents worse responses. The individual responses to the answered items were summed and standardized for a total score and then transformed to a 0- to 100- point scale (0=worst; 100=better) for ease of interpretation. A positive change from Baseline indicates that quality of life improved.	Baseline, Weeks 4, 8, 12, 18, 26 and 30/EOT

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Furiex Pharmaceuticals, Inc

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 29, 2012

Primary Completion (Actual)

January 9, 2014

Study Completion (Actual)

January 9, 2014

Study Registration Dates

First Submitted

March 8, 2012

First Submitted That Met QC Criteria

March 13, 2012

First Posted (Estimate)

March 14, 2012

Study Record Updates

Last Update Posted (Actual)

July 30, 2018

Last Update Submitted That Met QC Criteria

July 27, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

27018966IBS3002
2012-001601-24 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Irritable Bowel Syndrome

ProgenaBiome

Recruiting

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS

Irritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditions

United States
Clasado
CR2O B.V.

Recruiting

GOS to Reduce Symptom Severity in IBS (EGIS)

Irritable Bowel Syndrome | Irritable Bowel Syndrome - Constipation | Irritable Bowel Syndrome - Diarrhoea | Irritable Bowel Syndrome - Mixed

Belgium, Netherlands, United Kingdom
Istanbul Medipol University Hospital
Tepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaborators

Recruiting

Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome

Irritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Mixed

Turkey
Federal Stare Budgetary Scientific Institution,...
I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...

Completed

Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Mixed

Russian Federation
University of California, Los Angeles

Completed

FODMAP Reintroduction in Irritable Bowel Syndrome

Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel Habits

United States
University of Vienna

Completed

Effects of Fasting and Hydro Colon Therapy Plus Probiotics on GI Microbiota in Intolerances and Irritable Bowel Syndrome (MicFFGAH2013)

Irritable Bowel Disease

Austria
Thomayer University Hospital
Charles University, Czech Republic

Active, not recruiting

Faecal Microbiota Transplantation in Irritable Bowel Syndrome (MISCEAT)

Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome Mixed

Czechia
Shahid Beheshti University of Medical Sciences

Completed

Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome

Irritable Bowel Disease

Iran, Islamic Republic of
GlaxoSmithKline

Completed

Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers

Irritable Bowel Syndrome (IBS) | Irritable Colon

United States
Universidad Autonoma de Chihuahua

Not yet recruiting

To Study the Effect of Short-chain Fructooligosaccharides in Women With Irritable Bowel Syndrome

Irritable Bowel Syndrome | Constipation-predominant Irritable Bowel Syndrome | Diarrhea- Irritable Bowel Syndrome

Clinical Trials on Eluxadoline

Allergan

Enrolling by invitation

A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Irritable Bowel Syndrome

United States
Temple University
Allergan

Withdrawn

Investigation of Eluxadoline for Diabetic Diarrhea

Diabetes | Diarrhea | Diabetic Diarrhea

United States
University of North Carolina, Chapel Hill
Allergan

Withdrawn

Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence (ELXDFI)

Diarrhea | Fecal Incontinence | Urge Incontinence | Anal Incontinence | Accidental Bowel Leakage
Allergan

Completed

Eluxadoline Bile Acid Malabsorption (BAM) Study

Irritable Bowel Syndrome With Diarrhea

United States
Allergan

Completed

Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use

Irritable Bowel Syndrome With Diarrhea

United States, Canada
Furiex Pharmaceuticals, Inc

Completed

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Irritable Bowel Syndrome

United States, Canada, United Kingdom
AbbVie

Recruiting

Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

Irritable Bowel Syndrome

United States, Canada, Poland, United Kingdom, Hungary, Bulgaria, Netherlands
Furiex Pharmaceuticals, Inc

Completed

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

Irritable Bowel Syndrome

United States
University of North Carolina, Chapel Hill
National Institute of Environmental Health Sciences (NIEHS)

Completed

Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure (Gammoz)

Allergic Asthma

United States
John H. Stroger Hospital
Eli Lilly and Company

Completed

Insulin Therapy in the Hospital Comparing Two Protocols

Diabetes Mellitus, Type 2

United States

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Enrollment (Actual)

Phase

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Publications and helpful links

General Publications

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Clinical Trials on Irritable Bowel Syndrome

Clinical Trials on Eluxadoline

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malta

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations